Background: Hospitalizations for acute bacterial skin and skin structure infection (ABSSSI) in children are increasingly frequent, but little is known about antibiotic utilization. In adults ...

Ceftobiprole was turned down by the FDA in 2009 for ABSSSI when the drug was partnered with Johnson & Johnson’s Janssen Cilag unit. It has subsequently been approved as Zevtera or Mabelio in ...

Basilea will seek approval of ceftobiprole for SAB as well as acute bacterial skin and skin structure infection (ABSSSI) based on the results of the earlier TARGET study which showed non ...

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with ...

The trial is testing the efficacy of the RECCE 327 topical gel (R327G) applied once daily for seven or 14 days to areas infected by ABSSSI (bacterial infection of the skin and its related tissues).

Recce Pharmaceuticals Ltd (ASX:RCE) has seen its share price move up more than 1% on Tuesday’s news that the company successfully dosed all 30 participants in its Phase II clinical trial of a gel to ...

StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.